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A B S T R A C T
Background
Oral cancer is an important global healthcare problem, its incidence is increasing and late-stage presentation is common. Screening
programmes have been introduced for a number of major cancers and have proved effective in their early detection. Given the high
morbidity and mortality rates associated with oral cancer, there is a need to determine the effectiveness of a screening programme
for this disease, either as a targeted, opportunistic or population based measure. Evidence exists from modelled data that a visual oral
examination of high-risk individuals may be a cost-effective screening strategy and the development and use of adjunctive aids and
biomarkers is becoming increasingly common.
Objectives
To assess the effectiveness of current screening methods in decreasing oral cancer mortality.
Search methods
The following electronic databases were searched: the Cochrane Oral Health Group Trials Register (to 20 May 2010), the Cochrane
Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 2), MEDLINE via OVID (1950 to 20 May
2010), EMBASE via OVID (1980 to 20May 2010) and CANCERLIT via PubMed (1950 to 20May 2010). There were no restrictions
regarding language or date of publication.
Selection criteria
Randomised controlled trials (RCTs) of screening for oral cancer or potentially malignant disorders using visual examination, toluidine
blue, fluorescence imaging or brush biopsy.
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Data collection and analysis
The original review identified 1389 citations and this update identified an additional 330 studies, highlighting 1719 studies for
consideration.Only one studymet the inclusion criteria and validity assessment, data extraction and statistics evaluationwere undertaken
by six independent review authors.
Main results
One 9-year RCT has been included (n = 13 clusters: 191,873 participants). There was no statistically significant difference in the
age-standardised oral cancer mortality rates for the screened group (16.4/100,000 person-years) and the control group (20.7/100,000
person-years). A 43% reduction inmortality was reported between the intervention cohort (29.9/100,000 person-years) and the control
arm (45.4/100,000) for high-risk individuals who used tobacco or alcohol or both, which was statistically significant. However, this
study had a number of methodological weaknesses and the associated risk of bias was high.
Authors’ conclusions
Although there is evidence that a visual examination as part of a population based screening programme reduced the mortality rate
of oral cancer in high-risk individuals, whilst producing a stage shift and improvement in survival rates across the population as a
whole, the evidence is limited to one study and is associated with a high risk of bias. This was compounded by the fact that the effect
of cluster randomisation was not accounted for in the analysis. Furthermore, no robust evidence was identified to support the use of
other adjunctive technologies like toluidine blue, brush biopsy or fluorescence imaging within a primary care environment. Further
randomised controlled trials are recommended to assess the efficacy, effectiveness and cost-effectiveness of a visual examination as part
of a population based screening programme.
P L A I N L A N G U A G E S U M M A R Y
Screening programmes for the early detection and prevention of oral cancer
There is a need to understand whether screening programmes could detect oral cancer earlier and so reduce the number of deaths
from this disease. Cancer of the mouth is becoming increasingly common and has a low survival rate, as many patients present with
advanced disease. Screening the general population for oral cancer might make it possible to detect cases earlier. The most common
method is visual inspection by a clinician, but other techniques include the use of a special blue “dye”, the use of imaging techniques
and measuring biochemical changes to normal cells. The review found that overall there is not enough evidence to decide whether
screening by visual inspection reduces the death rate for oral cancer, and there is no evidence for other screening methods. However,
there is some evidence that it might help reduce death rates in patients who use tobacco and alcohol, although the only included study
may be effected by bias.
B A C K G R O U N D
Oral cancer is the 6thmost common cancer globally and represents
a group of conditionswith a range of sites and a varied aetiology. Its
annual estimated incidence is approximately 275,000, but unlike
many other cancers, its incidence is increasing (Warnakulasuriya
2009). There is a wide geographic variation in the incidence of the
disease with two-thirds of the burden born by developing countries
such as South and South-East Asia, Latin America and Eastern
Europe. However, the incidence continues to rise in the West
(IARC 2010) and the age standardised incidence of oral cancer in
Western Europe has steadily increased over the past two decades
(Boyle 2005).Within the EU countries the highest male incidence
rates are found in France and Hungary, whilst the lowest rates are
found in Greece and Cyprus (IARC 2010). India, Sri Lanka and
Pakistan has the highest level of the disease, making it the most
commoncancer formen in these countries and accounts up to30%
of all new cases of cancer compared to 3% in the United Kingdom
(UK) and 6% in France (Cancer Research UK). The age adjusted
incidence rate from these countries cancer registries range from3.4
to 13.8 per 100,000 in these countries (Ministry of Health 2005;
Warnakulasuriya 2009). The incidence of oral cancer for men in
Brazil is second only to France and India with an estimated crude
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rate of 11 per 100,000. In the UK, the incidence of oral cancer
is increasing (Conway 2006; Doobaree 2009) and 4926 cases of
oral cancer were diagnosed in 2005 (Cancer Research UK). This
represents a doubling of the number of cases seen in 1989 and
represents a year on year increase of approximately 2.7% per year
(Warnakulasuriya 2009). The incidence of oral cancer is strongly
related to social and economic deprivation (Scully 2009; Conway
2010a), with the highest rates occurring in themost disadvantaged
sections of the population. Across Europe, inequalities tend to be
observed among men, particularly in the UK and Eastern Europe
(Conway 2010b).
Important risk factors in the development of the disease are to-
bacco, betel quid, alcohol, age, gender and sunlight, although a
role for candida and the human papilloma virus has also been
documented (Scully 2009). Increased consumption of alcohol has
been implicated in the increasing incidence of the disease in the
UK (Hindle 2000) at a time when tobacco use is falling (Ogden
2005), despite the precise mechanism remaining unclear (Ogden
1998). When tobacco and alcohol use are taken together, the car-
cinogenic action of tobacco and alcohol is synergistic, with heavy
drinkers and smokers having 38 times the risk of developing oral
cancer compared to abstainers (Blot 1988). In addition, it is con-
sidered to be of particular importance in the development of ma-
lignancy in younger cohorts (Petti 2005), given the volume of
spirits consumed in binge drinking. Historically the risk of devel-
oping oral cancer increased with age, however, the age band with
the highest incidence (26.8%) in the United States of America
from 2003 to 2007 was between 55 and 64 years of age (SEER
2010). In contrast, many patients from high-incidence countries
are below the age of 40 years of age (Warnakulasuriya 2009) and
the incidence of oral cancer diagnosed in men in their 40s and 50s
has doubled in the UK (Cancer Research UK; Doobaree 2009)
and in many countries in the European Union.
Of equal concern to the increasing incidence, is the relative stability
of the age standardised mortality rates. This is unlike the falling
rates for cancer of the breast and colon (Cancer Research UK),
despite advances in surgical and management techniques. The
5-year survival rates for most countries is approximately 50% (
Warnakulasuriya 2009). These have been estimated at 3 to 4 per
100,000 men and 1.5 to 2.0 per 100,000 for women respectively
(Warnakulasuriya 2009). Mortality rates from oral cancer have
also increased in certain European countries (La Vecchia 2004).
Stage at diagnosis significantly affects 5-year survival, with survival
rates approaching80%for stage I disease dropping significantly for
stage IV disease (Rusthoven 2010). This is further compounded
by the inaccessibility of the tumour. In addition, the morbidity
associated with surgery is high, the rate of second primary tumours
in these patients is greater than any other type of cancer (3 to
7% per annum) (Day 1992) and is more often the cause of death
(Lippman 1989). The most important determinant factor behind
these dire statistics is diagnostic delay (Onizawa 2003; McLeod
2005), as over 60%of patients present with stage III and IV disease
(Lingen 2008), meaning that their management is complex and
multidisciplinary.
Prevention strategies are important to meet theWorld Health Or-
ganisation’s (WHO) resolution to incorporate oral cancer into na-
tional cancer control programs (Petersen 2009). Although it is im-
portant to continue to clarify the public health message and pro-
mote primary prevention, determining the feasibility of a national
screening programme is an important step in the prevention of
the disease. The National Screening Committe define screening
as “a process of identifying apparently healthy people who may
be at increased risk of a disease or condition” (NSC 2010). Pro-
grammes for major cancers, such as breast, cervical and now bowel
cancer have effectively improved the mortality rates and helped to
decrease the incidence of these cancers (Gøtzsche 2006; Hewitson
2007). Screening can be undertaken across the whole population,
opportunistically, when individuals are attending for some other
purpose, or selectively, where high-risk groups are targeted.
Screening is predicated on the idea that malignancy is preceded by
clinically evident lesions, which if identified early and removed,
can either prevent their malignant transformation or reduce their
staging. The majority of oral carcinomas are preceded by vis-
ible lesions, known as potentially malignant disorders (PMDs)
(Warnakulasuriya 2007; van der Waal 2009) that exhibit oral ep-
ithelial dysplasia associated with a number of different disease
processes (Scully 2009). Table 1 highlights the different types of
potentially malignant disorders (PMDs) that were considered by
the WHO’s Working Party on Oral Cancer and Precancer to be
important (Warnakulasuriya 2007). The most common form of
PMD is leukoplakia (Napier 2008), which has an estimated global
prevalence of 2.6% (95%confidence interval (CI): 1.72 to 2.74%)
(Petti 2003). However, the extent and rate of progression of dys-
plasia in leukoplakia is not uniform and can vary from site to site
and within the same lesion (Napier 2008).
The overall malignant transformation rate for oral leukoplakia is
approximately 5% (Scully 2009). These variations in the disease
process and the extent of dysplastic change in PMDs mean that
the natural history of oral cancer is not fully understood, although
there remains a consensus in the literature that the majority of
cancers are preceded by a detectable preclinical phase (Napier
2008).
Although there has been no randomised controlled trial (RCT) in
any Western or low-prevalence population (Brocklehurst 2010a),
Speight et al used simulation modelling and suggested that an
oral examination of high-risk individuals may be a cost-effective
screening strategy (Speight 2006). A systematic review of a visual
examination demonstrated an overall sensitivity of 0.85 and speci-
ficity of 0.97 (Downer 2004) and the authors concluded that vi-
sual screening compares well with cervical screening and mam-
mography, which had sensitivities and specificities in the order of
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0.80 and 0.98, respectively. In addition, a visual screen is not sur-
gically invasive, is painless and has been found to be acceptable.
Other adjunctive and diagnostic aids can be grouped into visual
staining (toluidine blue), oral cytology using brush biopsy and a
number of light-based techniques (e.g. ViziLite [Zila Pharmaceu-
ticals, AZ, USA] and VELscope [LED Dental Inc, BC, Canada])
(Brocklehurst 2010a).
The RCT provides the strongest level of evidence on which to
base clinical decisions (Clarkson 2003) and so represent a level of
rigor that is appropriate for assessing the effectiveness of any test or
programme. As with other cancers, screening for oral cancer and
PMD has potential advantages and disadvantages (Speight 1992).
Screening and treatment may offer the opportunity to reduce the
incidence of invasive lesions and also could help in decreasing the
mortality rates associated with oral cancer. In addition, Speight et
al demonstrated that targeting high risk groups could result in a
pronounced increase in the Quality Adjusted Life Years saved and
any associated stage shifts could produce significant cost savings
(Speight 2006). However, screening also has the potential to gen-
erate false positives and false negatives (Wilson 1968). In a system-
atic review of the literature, Kujan et al concluded that there was
insufficient evidence to support or refute the use of screening for
oral cancer in the general population (Kujan 2005). As a result,
the purpose of this update is to determine whether the evidence
base has changed. An up-to-date systematic review of the research
evidence was therefore undertaken.
O B J E C T I V E S
To assess the effectiveness of screening programmes in detecting
oral cancer and potentially malignant disorders.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of screening programmes for
the early detection of oral cancer or potentially malignant disorder
(PMD).
Types of participants
Participants involved in mass, high-risk and opportunistic screen-
ing programmes were included.
Types of interventions
Any screening programme for the detection of oral cancer or PMD
was considered, but they had to be compared to a control group
which do not receive a screen. These included:
• visual screening;
• visual staining using toluidine blue;
• oral cytology using brush biopsies;
• fluorescence imaging and light based techniques.
As the review was not determining the diagnostic accuracy of the
interventions per se, the exact definition of a positive case in each
of these categories was not defined. To do so may have limited the
number of studies reviewed. As a result, each study was assessed
on an individual study by study basis.
Types of outcome measures
The primary outcome considered in this review will be oral cancer
specific mortality.
Other outcomes included were:
• incidence of oral cancer or PMD;
• mortality at 3 or more years;
• stage at diagnosis;
• harms of screening (including adverse outcomes from false
positive or false negative results on initial screen);
• cost data (where reported).
Search methods for identification of studies
Electronic searches
For the identification of studies included or considered for this
review, detailed search strategies were developed for each database
searched. These were based on the search strategy developed for
MEDLINE (OVID) but revised appropriately for each database
(see Appendix 1). The search strategies for MEDLINE and CAN-
CERLIT used a combination of controlled vocabulary and free
text terms. They were linked with the Cochrane Highly Sensi-
tive Search Strategies (CHSSS) for identifying RCTs in MED-
LINE: sensitivity maximising versions (2009 revision) as refer-
enced in Chapter 6.4.11.1 and detailed in boxes 6.4a and 6.4.c of
the Cochrane Handbook for Systematic Reviews of Interventions Ver-
sion 5.0.2 (updated September 2009) (Higgins 2009). The search
of EMBASE was linked to the Cochrane Oral Health Group filter
for identifying RCTs.
Databases searched
The following electronic databases were searched.
• The Cochrane Oral Health Group’s Trials Register (to 20
May 2010) (see Appendix 2).
4Screening programmes for the early detection and prevention of oral cancer (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• CENTRAL (The Cochrane Library, 2010, Issue 2) (see
Appendix 3).
• MEDLINE via OVID (1950 to 20 May 2010) (see
Appendix 1).
• EMBASE via OVID (1980 to 20 May 2010) (see Appendix
4).
• CANCERLIT via PubMed (1950 to 20 May 2010) (see
Appendix 5).
Searching other resources
Two high yield journals, Community Dental Health and Com-
munity Dentistry and Oral Epidemiology were handsearched. In
addition, the following journals were handsearched from the date
of the last review (2006 to 2010).
• Oral Oncology




There were no non-English papers that required translation. Had
such trials been identified theywould have been translated through
The Cochrane Collaboration.
Unpublished trials
The bibliographies of included papers and relevant review articles
were checked for studies not identified by the search strategies
above. The authors of identified and included studies were also
contacted to identify unpublished or ongoing trials.
Data collection and analysis
Selection of studies
The titles and abstracts obtained from initial electronic searches
were scanned for relevance independently by two of the review
authors (Paul Brocklehurst (PRB), Anne-Marie Glenny (AMG)).
Reports from the studies that fulfilled the inclusion criteria were
obtained. When there was insufficient data in the study title to
determine whether a study fulfilled the inclusion criteria, the full
reportwas obtained and assessed independently by the same review
authors. Disagreement was resolved by discussion.
Data extraction and management
All studies meeting the inclusion criteria underwent data extrac-
tion and an assessment of risk of bias was made. Studies rejected
at this and subsequent stages were recorded in the table of ex-
cluded studies. Data from each included study was extracted inde-
pendently using the tool developed and reported in Kujan 2005.
Differences were again resolved by discussion. If a single publica-
tion reported two or more separate studies, then each study was
extracted separately. If the findings of a single study were spread
across two or more publications, then the publications were ex-
tracted as one. For each study with more than one control or
comparison group for the intervention, the results were extracted
for each intervention arm. For each trial the following data were
recorded.
• Year of publication, country of origin and source of study
funding.
• Details of the participants including demographic
characteristics and criteria for inclusion.
• Details on the type of intervention and comparisons.
• Details on the study design.
• Details on the outcomes reported, including method of
assessment.
Assessment of risk of bias in included studies
For the studies included in this review assessment of risk of bias
was conducted by four review authors (PRB, AMG, Simon Shep-
herd (SS) and Graham Ogden (GO)) using the Cochrane risk of
bias assessment tool. The domains that were assessed for each in-
cluded study were: sequence generation, allocation concealment,
blinding, completeness of outcome data, risk of selective outcome
reporting and risk of other potential sources of bias.
A description of the domains was to be tabulated for each included
trial, along with a judgement of low, high or unclear risk of bias.
For example, criteria for risk of bias judgements regarding allo-
cation concealment are given below as described in the Cochrane
Handbook for Systematic Reviews of Interventions 5.0.2 (Higgins
2009).
• Low risk of bias - adequate concealment of the allocation
(e.g. sequentially numbered, sealed, opaque envelopes or
centralised or pharmacy-controlled randomisation).
• Unclear risk of bias - unclear about whether the allocation
was adequately concealed (e.g. where the method of concealment
is not described or not described in sufficient detail to allow a
definite judgement).
• High risk of bias - inadequate allocation concealment (e.g.
open random number lists or quasi-randomisation such as
alternate days, date of birth, or case record number).
A summary assessment of the risk of bias for the primary outcome
(across domains) across studies was undertaken (Higgins 2009).
Within a study, a summary assessment of low risk of bias was given
when there was a low risk of bias for all key domains, unclear risk
of bias when there was an unclear risk of bias for one or more
key domains, and high risk of bias when there is was a high risk
of bias for one or more key domains. Across studies, a summary
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assessment was rated as low risk of bias when most information
was from studies at low risk of bias, unclear risk of bias when most
information was from studies at low or unclear risk of bias, and
high risk of bias when the proportion of information was from
studies at high risk of bias sufficient to affect the interpretation of
the results.
Measures of treatment effect
For dichotomous outcomes, the estimate of effect of an interven-
tion was expressed as risk ratios together with 95% confidence
intervals (CIs). For continuous outcomes, mean differences and
95% CIs were used to summarise the data for each group.
Unit of analysis issues
Where cluster randomised trials were included, analysis was to be
undertaken, whenever feasible, at the same level as randomisation,
or at the individual level accounting for the clustering.
Assessment of heterogeneity
The significance of any discrepancies in the estimates of the treat-
ment effects from the different trials was to be assessed by means
of Cochran’s test for heterogeneity and heterogeneity would have
been considered significant if P < 0.1 (Higgins 2009). The I2 statis-
tic, which describes the percentage total variation across studies
that is due to heterogeneity rather than chance, was used to quan-
tify heterogeneity with I2 over 50% being considered substantial
heterogeneity (Higgins 2009).
Assessment of reporting biases
If there had been sufficient numbers of trials (more than 10) in any
meta analysis, publication bias would have been assessed according
to the recommendations on testing for funnel plot asymmetry as
described in the Cochrane Handbook (Higgins 2009).
Data synthesis
Where appropriate, meta-analysis was applied to the outcomes
(minimum of three RCTs). Risk ratios were to be combined for
dichotomous data, andmean differences for continuous data using
a random-effects model, if data had allowed.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
The original search of MEDLINE via OVID (1966 to September
2002) that the first Cochrane review undertook revealed 1389
citations and the search conducted for the update revealed 1719
studies (to June 2010). However, initial screening of these titles
only revealed 32 potentially relevant articles which were selected
for review. Following the screening of these abstracts only one
study met the inclusion criteria, which had been identified earlier
by the original review (Sankaranarayanan 2000).
Searches of EMBASE,CANCERLIT, The Cochrane Central Reg-
ister of Controlled Trials (CENTRAL) (The Cochrane Library
2010), the Cochrane Oral Health Group’s Trials Register and bib-
liographies of review articles did not reveal any further relevant
studies that had not been identified by the MEDLINE search.
Similarly, handsearching for oral cancer screening in the identi-
fied journals did not identify any further studies. The principal
investigator of the included trial (Dr Sankaranarayanan) was also
contacted and no other trials were identified that had mortality
due to oral malignancy as its outcome measure.
The included study was designed to have an 80% power at the
5% significance level to detect a 35% reduction in the cumulative
mortality rate of oral cancer in 12 years of enrolment between the
intervention and the control groups. The study commenced in
October 1995 and three rounds of screening at 3-year intervals
were planned for the study. The first round was completed inMay
1998 and the secondwas completed in June 2002. The final (third)
round was completed in October 2004.
In this project (Trivandrum Oral Cancer Screening Study) all par-
ticipants (n = 191,873) were apparently healthy residents aged 35
years or older living in 13 clusters in rural areas of Trivandrum city,
Kerala, India. Those who were bedridden, suffering from open tu-
berculosis or other debilitating diseases and those diagnosed with
oral cancer prior to entry into the study were excluded. In each
cluster the number of eligible participants varied from 8000 to
18,500. These clusters were allocated into an intervention arm (n
= 7) and a control arm (n = 6) by blocked randomisation.
The intervention group in the third round of screening consisted
of 96,517 persons, 41,540 of whomweremale, and 54,977 female
(Table 2). The participation rate for screening at least once was
91%, males (86%) and females (94%). Of the screened subjects
5.9% (n = 5145) had referable lesion. 63% (3218) of the screen
positive subjects complied with referral (Table 3).
The control group consisted of 95,356 persons. Health workers
were initially trained and provided with two simple published
manuals on oral visual examination with colour photographs and
descriptions of various oral lesions. Eligible participants were in-
terviewed and information relating to demographic, social and
personal habits including the use of paan, tobacco, alcohol and
dietary supplements was recorded. Tobacco and alcohol cessation
advice was provided as appropriate.
Oral visual inspections were performed in daylight with the help
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of a flashlight. All the intraoral sites were carefully examined and
palpated and the neck was also palpated to detect enlarged lymph
nodes. The findings were recorded as normal, non-referable lesions
and referable lesions.
Participants who had a positive screen were then referred to be ex-
amined by dentists or physicians for confirmation of the positive
screen, although it is unclear whether these clinicians were also
trained in the recognition of oral cancer or potentially malignant
disorders. Oral biopsies were performed in those with clinically
confirmed homogeneous leukoplakias, non-homogeneous leuko-
plakias, oral submucous fibrosis and oral cancers. Surgical excision
was carried out for leukoplakia wherever possible. All potentially
malignant disorders were regularly reviewed concerning the pos-
sibility of surgical excision and to assess any regression or pro-
gression. Oral cancer mortality was reported as the main outcome
measure.
The control group clusters were also visited by a “control health
worker” for baseline recruitment, who recorded the same sociode-
mographic information and measured height, weight, blood pres-
sure and respiratory peak flow measurements. However, the con-
trol health workers were not trained in how to undertake a visual
oral inspection.
Risk of bias in included studies
Allocation
Sequence generation
The randomisation procedure was conducted using restricted
block randomisation. The exact detail of this process was not pro-
vided, although the clusters were grouped into blocks of four and
allocated at random to screening or non-screening groups from
the six possible combinations available to each block of four. Clus-
tering was not accounted for in the analysis in accordance with
the guidance from Cochrane (Section 16.3.3, Higgins 2009).
Allocation concealment
No detail of allocation concealment was provided, although the
principal investigator confirmed that this was not undertaken.
Blinding
Blinding of outcome assessment
No blinding was described in the study, but the review authors
judge that the outcome and its measurement are unlikely to be
influenced by this. As a result, the risk of bias based on the lack of
blinding is considered to be low.
Incomplete outcome data
Withdrawals and drop-outs were not described clearly in this study
and this missing data will have increased the risk of bias. Of those
who were referred with positive-screen lesions, 63% of individu-
als complied with referral, males (1604: 60%) and females (1614:
65%) (Table 3). However, the analysis was carried out on an in-
tention-to-treat (ITT) basis.
Selective reporting
The study protocol was not made available, but it appears that
the published reports include all the expected and pre-specified
outcome measures.
Other potential sources of bias
Positive cases were referred to General Practitioners and General
Dental Practitioners to make a diagnosis, but it is unclear whether
standardised criteria were used by these clinicians or whether they
had received any formal training or standardisation in the identi-
fication of positive lesions.
It is stated that subjects with confirmed oral cancer and poten-
tially malignant disorders (PMDs) were biopsied and those with
confirmed oral cancer were referred. However, although not de-
tailed in the first cycle, only 26.4% of subjects with a potentially
malignant disorder (PMD) had a biopsy in the second cycle and
only 26% in the third cycle. It is not clear whether all suspected
oral cancer cases did receive a biopsy, but given the definition of
“interval cases” in the third paper, it would appear not. In addi-
tion, it is stated in the third paper that the reference investigation
for final diagnosis was clinical examination by doctors or histol-
ogy or both. As it is not possible to diagnose early malignancy by
visual appearance alone, this may have led to substantial under-
reporting of oral cancer. The lack of a histological diagnosis for
many of the PMDs also makes it difficult to accurately assess the
correct diagnosis and true prevalence of these disorders.
Prevalence of PMD and mortality data is only provided in detail
for the first two cycles only. The third paper presents the results
over the three cycles from 1996 to 2004 and so does not provide
individual detail about the results of the third cycle. It is not clear
why this was the case.
In the included study the health workers reported on 24 baseline
variables including multiple age strata, occupation, education, in-
come, household belongings such as television and personal habits
of chewing, smoking, and drinking. The intervention and con-
trol cohorts appear to have been well matched for the stratified
variable age at the baseline. However, the distribution of income,
education, use of tobacco and alcohol varied across the interven-
tion and control groups, with the former demonstrating higher
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levels of consumption Table 2. Men smoked and drank alcohol
more than females in both groups, but the prevalence of chewing
tobacco was not as marked across gender differences. Although,
such differences in baseline variables might be expected to occur in
cluster randomised studies, the differences between the numbers
who used tobacco and alcohol need to be borne in mind when
interpreting the results.
Effects of interventions
The included study reported data on oral cancer incidence, disease
specific-mortality, and stage at diagnosis after 9-years follow-up.
Data on quality of life and all cause mortality was not reported.
Oral cancer incidence
Among the 87,829 participants screened in the intervention
group, 5145 (5.9%) were found to have referable lesions. Of these,
3218 (63%) compliedwith the referral criteria for confirmatory ex-
amination by dentists or medical officers in special clinics. Healthy
mucosa or benign lesions were found in 835 (26%). The number
of PMDs was 2252 (70%) (lichen planus (n = 51), homogenous
leukoplakia (n = 795) and submucous fibrosis (n = 509)) and oral
cancer 131/3218 (4%). The detection rate of PMD and oral can-
cer in the first, second and third rounds of screening were 28.0,
11.6 and 11.3 per 1000 screened subjects respectively. Examina-
tion of the Trivandrum cancer registry recorded 363 patients with
oral cancer. Two hundred and five patients were in the interven-
tion group and 158 in the control group. The crude incident rate
of oral cancer was 43.7 per 100,000 person-years in the interven-
tion arm and 37.6 per 100,000 person-years in the control group
(Table 4).
Test performance
Across the nine years of the programme, the reported sensitivity
of the visual examination in detecting oral cancer was 64% (131/
205) (Table 4). No information on the specificity or the positive
predictive value of the programme was recorded. However, the
latter was calculated based on the published data from the study as
the number of screen-selected oral cancers as a proportion of total
screen positive subjects (confirmed by biopsy), which was 74% for
oral cancer.
Oral cancer mortality
There was no statistically significant difference in the mortality
rate for oral cancer between the intervention group and control.
Over the 9-year period, 77 of 205 subjects with oral cancer in
the intervention group and 87 of the 158 cases in the control
group died, which represents a mortality rate of 16.4 and 20.7 per
100,000 person years respectively (Table 4).
However, for individuals that used tobacco, alcohol or both, there
was a significant reduction of 43% in mortality rates for men from
42.9 per 100,000 person years in the control group to 24.6 per
100,000 person years in the intervention group (Table 5). For
women, there was a 22% reduction, from50.7 to 39.4 per 100,000
person years, but this did not reach significance (Table 5).
Survival
The authors also examined survival rates by comparing the pro-
portion of patients alive 5 years after diagnosis across the two
groups. A significantly higher 5-year survival rate was reported in
the intervention group (50%) than in the control group (34%) (P
= 0.009).
Stage shift at diagnosis
There was a statistically significant stage shift in the cancers that
were diagnosed in the intervention group, based on the criteria of
the International Union Against Cancer/American Joint Commit-
tee on Cancer (UICC/AJCC) clinical TNM stage was available.
In the intervention group, 42% of the cases were in stage I or II, as
opposed to 24% of cases in the control group (P = 0.004) (Table
6). On the other hand, 66% of cases in the control group were in
the stage III or IV compared to 41% of cases in the intervention
group (Table 6).
Cost effectiveness
The costs associated with the study were reported in a later study
(Subramanian 2009) (Table 7). The benefit produced by a screen
was 269.31 life years saved per 100,000 for all the individuals and
1437.64 for those at high risk. The incremental cost per life-year
saved was US$835 for all individuals, which reduced to US$156
for high-risk individuals. This fulfils the target set by the World
Health Organisation (WHO) Commission on Macroeconomics
and Health (WHO 2001), who define an intervention as being
cost effectivewhen its cost-effectiveness ratio is less than a country’s
gross domestic product per capita. Subramanian argues that this
provides good evidence that opportunistic screening of high-risk
groups may be feasible and cost effective (Subramanian 2009),
but there has been no randomised controlled trial in any Western
or low-prevalence population and the risk of bias of the included
study is high.
D I S C U S S I O N
The incidence of oral cancer is increasing in both developed and
developing countries (Warnakulasuriya 2009). Delays in diagnosis
and management persist (Onizawa 2003; McLeod 2005) and are
associated with a dramatic deterioration in 5-year survival rates.
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Effective primary and secondary prevention strategies are critical
in delivering the World Health Organisation’s (WHO) resolution
that oral cancer should be an integral part of national cancer con-
trol programs (Petersen 2009).
Given that the majority of oral carcinomas are preceded by visible
lesions (Scully 2009), determining the efficacy and effectiveness of
screening warrants attention, whilst balancing the potential ben-
efits with any potential negative consequences of any programme
(Wilson 1968).
Themost recentmeta-analysis of visual screening found aweighted
and pooled sensitivity of 84.8% (95% confidence interval (CI)
73.0 to 91.9) and specificity of 96.5% (95% CI 93.0 to 98.2)
(Downer 2004). In this systematic review, only prospective pop-
ulation level studies with gold standard verification were selected
and reports were excluded if at least one of the six inclusion criteria
were not met. Nine databases were searched and out of 481 papers,
only eight papers met this standard. However, there was consid-
erable heterogeneity in these studies, due to differences in the size
of the target populations, in the numbers of patients screened and
verified and the type of clinician used. Despite this, meta-analysis
regression showed no difference (P = 0.99) in the discriminatory
ability between these groups, although the authors highlight the
low number of studies and reported a lack of independence in two
of these eight papers.
These values of sensitivity and specificity for visual examination
have not been surpassed by any other type of method, such as vital
staining (toluidine blue), oral cytology or light-based techniques
(Lingen 2008; Patton 2008). More importantly, visual screening
is the only method that has been evaluated in primary care using
a randomised controlled trial design, on patients who are appar-
ently free from the disease (Lingen 2008). In Patton’s systematic
review, 23 studies met the inclusion criteria, yet there remained
insufficient evidence to support or refute the use of adjunctive
techniques to the visual examination (Patton 2008). In another re-
view, Lingen found that the majority of the published studies had
employed these techniques on patients who had already received
a diagnosis and that they did not improve upon the sensitivity or
specificity of the visual examination.
The aim of this Cochrane systematic review was to examine
whether screening for oral cancer reduced the mortality associated
with the disease. The original review identified 1389 citations and
this update identified an additional 330 studies (1719 studies to
June 2010). However, only one study (Sankaranarayanan 2000)
met the inclusion criteria, which had been identified earlier by the
original review.
As highlighted by Kujan, the Sankaranarayanan 2000 study was
found to have a number of methodological weaknesses that may
have introduced bias (Kujan 2005). These included a lack of de-
tail about the process of sequence generation to ensure random
assignment, no analysis of the impact of clustering on the results
and no detail about allocation concealment. In addition, the there
was no blinding of the outcome assessment and withdrawals and
drop-outs were not described. More importantly, of those who
were referred with screen-positive lesions, only 63% of individuals
complied with referral and it was unclear whether the clinicians
who saw these patients followed any standardised criteria. Finally,
only 26.4% and 26.0% of subjects had a biopsy in the second or
third cycle, respectively, with no detail being provided from the
first cycle. As it is not possible to diagnose early malignancy by
visual appearance alone, this may have led to substantial under-
reporting of oral cancer and the lack of a histological diagnosis
makes it difficult to accurately assess the correct diagnosis and
true prevalence of these disorders. Kujan also argues that the small
number of randomised clusters may have resulted in heterogene-
ity across the intervention and control groups and the close geo-
graphical proximity of the clusters may have led to contamination
(Kujan 2005).
The study reported a sensitivity of the visual examination in de-
tecting oral cancer was 64% and Kujan calculated a positive pre-
dictive value of 74% for the programme was recorded. Overall,
there was no statistically significant difference in themortality rate
for oral cancer between the intervention group and control over
the 9-year period. However, when high-risk individuals that used
tobacco, alcohol or both were compared with low-risk individuals,
there was a significant reduction of 43% in mortality rates for men
who had received a visual screen. Although substantial, the 22%
reduction in high-risk women was not significant. When these re-
sults are combined with the significant stage shift and survival rate
in the intervention group, it would appear that visual examination
could be effective at reducing mortality rates for oral cancer when
used within a targeted screening programme. However, this state-
ment needs to be read with caution given the potential sources
of bias identified above. In addition, it is also possible that the
improvement in survival rates with early stage oral cancer was due
to lead-time bias i.e. increasing the length of time that the indi-
vidual knows about their condition, without any effective increase
in survival. Without subtracting this period from the overall sur-
vival time for screened patients, early detection merely increases
the duration of the patients’ awareness of their disease without re-
ducing their mortality or morbidity. Numerous cancer-screening
procedures were thought to improve survival until lead-time bias
was addressed (Kay 1991).
Given the natural history of oral cancer and the variation in the
reduction in mortality rates between the intervention and control
groups in each of the three individual cycles (Sankaranarayanan
2000; Ramadas 2003; Sankaranarayanan 2005) it is also critical
to ensure that any future studies are undertaken over a sufficient
time scale to ensure there is adequate statistical power to detect
the effect size in mortality reduction.
The cost effectiveness of the Sankaranarayanan 2000 study was
reported in a later paper (Subramanian 2009). Again, the targeted
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approach was more effective, with 1437.64 life years saved per
100,000 high-risk individuals and an incremental cost per life-year
saved of US$156. According to the authors, this fulfils the target
set by the WHO Commission on Macroeconomics and Health,
who define an intervention as being cost effective when its cost-
effectiveness ratio is less than a country’s gross domestic product
per capita. The results also need to be read in context, given the
higher prevalence of the disease in the developing world. To date,
there has been no randomised controlled trial in any Western or
low-prevalence population, although Petti did not establish a sta-
tistically significant difference in prevalence of PMD between de-
veloping and developed nations (Petti 2003). Napier & Speight
argue that this may be due to the global use of tobacco (Napier
2008) and Lim also found a similar prevalence of PMD in a Gen-
eral Dental Practice setting in the United Kingdom (Lim 2003).
The consideration of both the benefits and harms of screening is
an essential component of any programme (Wilson 1968) and is
fundamental to the satisfactory introduction of any technology
into daily practice (Duffy 2001). The sensitivity reported in the
Sankaranarayanan 2000 study was relatively low (64%) compared
to Downer’s systematic review (Downer 2004) and false positives
may have unintended psychological consequences on the popula-
tion being screened, for example, increased levels of anxiety from
the false positive and along with the associated trauma of any un-
necessary investigations. However, these could be reduced by care-
ful patient management and by educating screened patients about
the positive benefits of screening (Speight 1992). Recent studies by
Brocklehurst, highlighted the need to train General Dental Prac-
titioners to discuss positive findings (Brocklehurst 2010b) and the
need for standardised criteria to avoid both under and over-referral
in clinical practice (Brocklehurst 2010).
The purpose of healthcare is to improve both the quantity and
quality of life (Kaplan 2005). The evidence from the Sankara-
narayanan 2000 study is that visual screening can impact upon
the former in high-risk individuals and can produce a significant
stage shift and survival rate. This is important as advances in the
management of the disease is more effective and cost effective for
early stage disease (Speight 2006; Rogers 2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our results suggest that there is insufficient evidence to recom-
mend inclusion or exclusion of screening for oral cancer using a
visual examination in the general population, in addition to that,
no robust evidence exists for adjunctive methods of screening,
toluidine blue, fluorescence imaging and brush biopsy, to be ei-
ther included or excluded. The data need to be supplemented by
further randomised controlled trials to provide the highest level of
evidence for practice.
In the meantime, as an alternative for a national based screen-
ing programme, regular opportunistic screening by visual exam-
ination applied by qualified healthcare providers for a high-risk
group might be effective in achieving an improvement outcome.
Systematic examination of the oral cavity by the general dental
practitioner or physician should remain an integral part of their
routine daily work.
Implications for research
Given the high risk of bias in the study included in this review, a
lack of randomised controlled studies associated with adjunctive
methods (e.g. brush biopsy, fluorescence imaging) and a lack of
understanding of the natural history of oral cancer, further ran-
domised controlled trials are recommended. These should ensure
the method of randomisation is accounted for in the analysis, that
there is adequate allocation concealment and standard interven-
tions for screening based on standardised criteria. In addition, the
use of fully qualified and trained teams, a clear follow-up proce-
dure and blinding of the outcome assessment should be utilised
as far as possible.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Sankaranarayanan 2000
Methods Randomised controlled trial, Kerala, India.
First round: 1995 to 1998.
Second round: 1998 to 2002.
Final round: 2002 to 2004.
Participants General population aged 35 years or older, all subjects 191,873 were apparently healthy
residents were grouped into intervention (n = 7 clusters, 96,517) and control (n = 6
clusters, 95,356)
Interventions Health workers interviewed the eligible subjects to extract specified information. Inter-
vention group: visual examination of the oral mucosa.
Control group: follow up to the end point (study is ongoing)
The intervention and control cohorts are being followed up by the Trivandrum popula-
tion-based cancer registry to determine the incidence and stage distribution of invasive
oral cancer, treatment given and mortality
Outcomes Oral cancer mortality was the major outcome. Further outcome measures were:
1. Participation: defined as “the number of eligible subjects screened as a proportion of
the total eligible in the intervention arm”.
2. Positivity rate: defined as “the proportion of screened subjects identified with referable
lesions”.
3. Detection rate: defined as “the number of subjects with lesions detected per 1000
screened subjects in the intervention group”.
4. Compliance with referral: defined as “the proportion of screen positive subjects re-
porting for diagnostic confirmation by dentists or physicians”.
5. Sensitivity, specificity, and positive predictive values
6. Program sensitivity and specificity: defined as “the number of screen-detected oral
cancers as a proportion of the total oral cancers in the intervention group”, “the pro-
portion of screen true-negative subjects among the total non-cancer-eligible subjects”
and “the number of screen-detected oral cancers as a proportion of total screen positive
subjects” respectively.
7. Incidence rate of oral cancers
8. Characteristics of oral cancers in the study group including: the maximum dimension
of lesions, regional lymph node involvement and International Union Against Cancer/
American Joint Committee on Cancer (UICC/AJCC) TNM stage grouping distribu-
tion.
9. Case fatality for oral cancer cases diagnosed during the study period: defined as “the
number of deaths among the total number of cases”
Notes
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Sankaranarayanan 2000 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Subjects were allocated by block randomi-
sation into 13 clusters but no detail is given
about how this process was undertaken




Yes No blinding, but the review authors judge
that the outcome and its measurement are
unlikely to be influenced by this. Consid-
ered low risk
Incomplete outcome data addressed?
All outcomes
No Not all participants attended for biopsy af-
ter screen (only 63% of screened positive
complied with referral to have a biopsy).
This missing data will have increased the
risk of bias
Free of selective reporting? Yes Protocol is not available, but it appears that
the published reports include all expected
and pre-specified outcomes
Free of other bias? Unclear Positive cases were referred toGeneral Prac-
titioners and General Dental Practition-
ers to make a diagnosis, but it is unclear
whether standardised criteria were used by
these clinicians or whether they had re-
ceived any training in identification of pos-
itive lesions
It is stated that subjects with confirmed
oral cancer and potentially malignant dis-
orders were biopsied and those with con-
firmed oral cancer were referred. However,
although not detailed in the first cycle, only
26.4% of subjects with a potentially malig-
nant disorder (PMD) had a biopsy in the
second cycle and only 26% in the third cy-
cle. It is not clear whether all suspected oral
cancer cases did receive a biopsy, but given
the definition of “interval cases” in the third
paper, it would appear not. In addition, it is
stated in the third paper that the reference
investigation for final diagnosis was clini-
cal examination by doctors or histology or
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Sankaranarayanan 2000 (Continued)
both. As it is not possible to diagnose early
malignancy by visual appearance alone, this
may have led to substantial under-report-
ing of oral cancer. The lack of a histological
diagnosis formany of the PMDs alsomakes
it difficult to accurately assess the correct
diagnosis and true prevalence of these dis-
orders
Prevalence of PMD and mortality data is
only provided in detail for the first two cy-
cles only. The third paper presents the re-
sults over the three cycles from 1996 to
2004 and so does not provide individual
detail about the results of the third cycle. It
is not clear why this was the case
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allen 1998 Letter to author.
Chamberlain 1993 Review study.
Chen 2004 Uncontrolled clinical mass screening study.
Cheng 2003 Randomised controlled trial (diagnostic use).
Eliezri 1988 Uncontrolled study (secondary care).
Garrote 1995 Uncontrolled study.
Gray 2000 Review.
Gupta 1986 Non randomised controlled study.
Gupta 1992 Non randomised controlled study.
Ikeda 1991 Uncontrolled study.
Ikeda 1995 Uncontrolled study.
Lavelle 2005 Review.
Martin 1998 Uncontrolled study.
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(Continued)
Miller 1988 Study in hamsters.
Moyer 1986 Uncontrolled study (diagnostic only).
Mullhaupt 2004 Non-randomised controlled study.
Nagao 2000 Uncontrolled study.
Nagao 2000a Uncontrolled study.
Nagao 2003 Uncontrolled mass screening study.
Patton 2003 Review.
Sankaranarayanan 1997 Review study.
Sankaranarayanan 2002 Observational, case control study.
Silverman 1984 Uncontrolled study.
Vahidy 1972 Uncontrolled study.
Zhang 2005 Observational study.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Important Potentially Malignant Disorders








Hereditary disorders such as dyskeratosis congenita and epidermolysis bullosa
Table 2. Comparison between the intervention and control groups after three cycles (1996 to 2004)
Study Intervention group Control group





Income (< 1500 rupees (US$35) per
month)
42,415 (49%) 30,849 (40%)
Occupation (manual workers) 68,645 (78%) 55,811 (71%)
Education 68,263 (78%) 64,291 (78%)
Age (years; mean (SD, range)) 49 (0.7, 48-50) 49 (0.8, 48-50)
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Table 3. Screening history
Screening history Male Female Total
Not screened 14% (5941) 5% (2921) 9% (8862)
Screened once 40% (16,744) 32% (17,599) 36% (34,343)
Screened twice 25% (10,274) 25% (13,936) 25% (24,210)
Screened thrice 21% (8581) 37% (20,521) 30% (29,102)
Number of subjects with refer-
able lesions
2675 2470 5145
Subjects complied with referral 60% (1604) 65.7% (1614) 63% (3218)
Table 4. Number of oral cancers diagnosed and associated mortality rate
Kerala project Intervention group Control group
Number of oral cancers 205
(Male: 107 and Female: 98)
158
(Male: 104 and Female: 54)
Number of screen detected cases 131 N/A
Deaths of oral cancer 77 87
Total number of participants 87,829 80,086
Case fatality rate 37.5% 55.1%
Crude incidence rate of oral cancer per 100,
000
43.7 37.6
Crude mortality rate from oral cancer per
100,000
16.4 20.7
Proportion of cancers at stage I/II1 41.5% 23.4%
1statistically significant P = 0.004
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Table 5. Oral cancer experience in high-risk individuals after three cycles (1996 to 2004)
Kerala project Intervention group Control group
Male Female Male Female
Person years of observa-
tion
150,702 83,703 128,102 59,179
Number of oral cancer
diagnosed
99 91 104 52
Deaths of oral cancer 37 33 55 30
Case-fatality rate 37.3% 36.3% 52.9% 57.7%
Crude incidence rate of
oral cancer per 100,000
65.7 108.7 81.2 87.9
Crude mortality
rate from oral cancer per
100,000
24.6 39.4 42.9 50.7
High risk individuals were defined as those who used tobacco, alcohol or both
Table 6. Stage shift due to the intervention in Kerala
Stage Intervention group Control group
Screen-detected Interval Non-responders Total
I 40 (31%) 9 (15%) 2 (13%) 51 (25%) 20 (13%)
II 23 (18%) 10 (17%) 1 (7%) 34 (17%) 17 (11%)
III 22 (17%) 12 (20%) 3 (20%) 37 (18%) 35 (22%)
IV 38 (29%) 24 (41%) 5 (33%) 67 (33%) 70 (44%)
Unknown 8 (6%) 4 (7%) 4 (27%) 16 (8%) 16 (10%)
Total 131 (100%) 59 (100%) 15 (100%) 205 (100%) 158 (100%)
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Table 7. Cost effectiveness of the screening programme in Kerala
Detail Cost of intervention less cost of control (US$)
Total cost per 100,000 individuals 224,964
Cost per additional cancer detected by the
screen
All individuals 4817
Cost per additional cancer detected by the
screen
High-risk individuals 9394
Cost per life-year saved by the screen All individuals 835
Cost per life-year saved by the screen High-risk individuals 156
Costs based on the calender year of 2004 (Subramanian 2009)
A P P E N D I C E S









9. (mouth or lip$ or tongue$ or gingiv$ or oropharynx or palate or cheek$).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
10. or/1-9
11. exp MOUTH NEOPLASMS/
12. exp PRECANCEROUS CONDITIONS/
13. (tumor$ or tumour$ or cancer$ or carcinoma$).mp. [mp=title, original title, abstract, name of substance word, subject heading
word, unique identifier]
14. malignan$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
15. dysplasia$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
16. (oral adj6 cancer$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
17. or/11-16
18. MASS SCREENING/
19. (visual$ adj screen$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
20. tolonium chloride.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
21. TOLONIUM CHLORIDE/
22. “toluidine blue”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
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23. exp TOLUIDINES/
24. “toluidine dye”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
25. (“brush biopsy” or “exfoliate cytology”).mp. [mp=title, original title, abstract, name of substance word, subject heading word,
unique identifier]
26. “fluorescent imaging”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
27. (“fluorescent dye$” or “fluorescent antibody technique” or fluorescence).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
28. prevent$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
29. screen$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
30. (early adj3 detect$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
31. or/18-30
32. 10 and 17 and 31
The above subject search was linked to the the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in
MEDLINE: sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of The Cochrane
Handbook for Systematic Reviews of Interventions, Version 5.0.2 [updated September 2009].
1. randomized controlled trial.pt.








10. exp animals/ not humans.sh.
11. 9 not 10
Appendix 2. Cochrane Oral Health Group Trials Register Search Strategy
((tumor* or tumour* or cancer* or carcinoma* or malignan*) AND (screen* or tolonium or “brush biopsy” or “exfoliative cytology”
or fluorescen* or “early detect*”))
Appendix 3. Cochrane Central Register of Controlled Clinical Trials (CENTRAL) Search Strategy
#1 MeSH descriptor MOUTH explode all trees
#2 MeSH descriptor LIP explode all trees
#3 MeSH descriptor GINGIVA this term only
#4 MeSH descriptor TONGUE explode all trees
#5 MeSH descriptor OROPHARYNX explode all trees
#6 MeSH descriptor HYPOPHARYNX explode all trees
#7 MeSH descriptor PALATE explode all trees
#8 MeSH descriptor CHEEK this term only
#9 (mouth* in All Text or lip* in All Text or tongue* in All Text or gingiv* in All Text or oropharnyx in All Text or palate* in All
Text or cheek* in All Text)
#10 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
#11 MeSH descriptor MOUTH NEOPLASMS explode all trees
#12 MeSH descriptor PRECANCEROUS CONDITIONS explode all trees
#13 (tumor* in All Text or tumour* in All Text or cancer* in All Text or carcinoma* in All Text)
#14 malignan* in All Text
#15 dysplasia* in All Text
#16 (oral in All Text near/6 cancer* in All Text)
#17 (#11 or #12 or #13 or #14 or #15 or #16)
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#18 MeSH descriptor Mass Screening explode all trees
#19 “visual* screen*” in All Text
#20 “tolonium chloride” in All Text
#21 MeSH descriptor TOLONIUM CHLORIDE this term only
#22 “toluidine blue” in All Text
#23 MeSH descriptor TOLUIDINES explode all trees
#24 “toluidine dye” in All Text
#25 (“brush biopsy” in All Text or “exfoliate cytology” in All Text)
#26 “fluorescent imaging” in All Text
#27 (“fluorescent dye*” in All Text or “fluorescent antibody technique” in All Text or fluorescence in All Text)
#28 prevent* in All Text
#29 screen* in All Text
#30 (early in All Text near/3 detect* in All Text)
#31 (#18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30)
#32 (#10 and #17 and #31)









9. (mouth or lip$ or tongue$ or gingiv$ or oropharynx or palate or cheek$).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
10. or/1-9
11. exp MOUTH NEOPLASMS/
12. exp PRECANCEROUS CONDITIONS/
13. (tumor$ or tumour$ or cancer$ or carcinoma$).mp. [mp=title, original title, abstract, name of substance word, subject heading
word, unique identifier]
14. malignan$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
15. dysplasia$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
16. (oral adj6 cancer$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
17. or/11-16
18. MASS SCREENING/
19. (visual$ adj screen$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
20. tolonium chloride.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
21. TOLONIUM CHLORIDE/
22. “toluidine blue”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
23. exp TOLUIDINES/
24. “toluidine dye”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
25. (“brush biopsy” or “exfoliate cytology”).mp. [mp=title, original title, abstract, name of substance word, subject heading word,
unique identifier]
26. “fluorescent imaging”.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
27. (“fluorescent dye$” or “fluorescent antibody technique” or fluorescence).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
28. prevent$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
29. screen$.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
30. (early adj3 detect$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]
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31. or/18-30
32. 10 and 17 and 31
The above subject search was linked to the Cochrane Oral Health Group filter for identifying RCTs in EMBASE via OVID:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.






12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/
16. HUMAN/
17. 16 and 15
18. 15 not 17
19. 14 not 18
Appendix 5. CANCERLIT via PubMed Search Strategy
#1 Search MOUTH [mh:exp]
#2 Search LIP [mh:exp]
#3 Search GINGIVA [mh:exp]
#4 Search TONGUE [mh:exp]
#5 Search OROPHARYNX [mh:exp]
#6 Search HYPOPHARYNX [mh:exp]
#7 Search PALATE [mh:exp]
#8 Search CHEEK [mh:exp]
#9 Search (mouth or lip* or tongue* or gingiv* or oropharynx or palate or cheek*)
#10 Search #1 or #2 or #3 pr #4 or #5 or #6 or #7 or #8 or #9
#11 Search MOUTH NEOPLASMS [mh:exp]
#12 Search PRECANCEROUS CONDITIONS [mh:exp]
#13 Search (tumor* or tumour* or cancer* or carcinoma*)
#14 Search malignan*
#15 Search dysplasia*
#16 Search “oral cancer*”
#17 Search #11 or #12 or #13 or #14 or #15 or #16
#18 Search MASS SCREENING [mh:exp]
#19 Search “visual* screen*”
#20 Search “tolonium chloride”
#21 Search TOLONIUM CHLORIDE [mh:noexp]
#22 Search “toluidine blue”
#23 Search TOLUIDINES [mh:exp]
#24 Search “toluidine dye”
#25 Search (“brush biopsy” or “exfoliate cytology”)
#26 Search “fluorescent imaging”
#27 Search (“fluorescent dye*” or “fluorescent antibody technique” or fluorescence)
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#28 Search prevent*
#29 Search screen*
#30 Search “early detect*”
#31 Search #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30
The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in
MEDLINE: sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.a of The Cochrane
Handbook for Systematic Reviews of Interventions, Version 5.0.2 [updated September 2009]:
#1 randomized controlled trial [pt]
#2 controlled clinical trial [pt]
#3 randomized [tiab]
#4 placebo [tiab]




#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10 animals [mh] NOT humans [mh]
#11 #9 NOT #10
WH A T ’ S N E W
Last assessed as up-to-date: 5 October 2010.
Date Event Description
6 October 2010 New citation required but conclusions have not changed New authorship.
6 October 2010 New search has been performed New searches and methodology. Review text, back-
ground and references brought up to date
H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 4, 2003
Date Event Description
18 June 2010 New search has been performed Converted to new review format.
25 May 2006 New citation required but conclusions have not changed This version includes a change in authors.
23 May 2006 New search has been performed The current review reflects the results of an update search
conducted in July 2005. No new trials were identified as
meeting the review’s inclusion criteria. However, a trial
presenting the final analysis for the one, previously in-
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(Continued)
cluded trial was identified. The conclusions of the review
remain the same
C O N T R I B U T I O N S O F A U T H O R S
Development of protocol based on the latest Cochrane guidance: Paul Brocklehurst (PRB).
Identification of studies: PRB, Anne-Marie Glenny (AMG).
Data extraction: PRB, AMG, Graham Ogden (GO) and Simon Shepherd (SS).
Assessment of risk of bias: PRB, AMG, GO, SS.
Data input/synthesis: PRB, AMG.
Writing of conclusions: PRB, AMG, OK, RJO, GO, PS, SS.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• The University of Manchester, UK.
• AlBaath University, Not specified.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Mass Screening [∗methods]; Mouth Neoplasms [∗diagnosis; mortality; prevention & control]; Physical Examination [methods]; Ran-
domized Controlled Trials as Topic
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MeSH check words
Humans
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